Form 4: Artiva Biotherapeutics COO, CLO, Secy, Compliance Off Jennifer Bush Reports Acquisition and Disposal of Shares

Jennifer Bush, COO, CLO, Secy, Compliance Off of Artiva Biotherapeutics, reports acquiring 86,650 shares of common stock and disposing of 159,449 shares on February 26, 2025.

Summary

• On February 26, 2025, Jennifer Bush, the COO, CLO, Secy, Compliance Off of Artiva Biotherapeutics, Inc., acquired 86,650 shares of common stock.
• The acquisition was related to a restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
• On the same day, Bush disposed of 159,449 shares of common stock.
• Following these transactions, Bush beneficially owns 159,449 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but the disposal of shares could be interpreted in different ways depending on the context.

Positives

• The acquisition of shares indicates continued alignment of the officer's interests with the company's performance.

Negatives

• The disposal of 159,449 shares could be perceived negatively by investors if it suggests a lack of confidence in the company's future performance, although the reason for disposal is not specified.

Risks

• The Form 4 filing itself doesn't inherently indicate risks, but the disposal of a significant number of shares by a company officer could raise concerns among investors if not properly explained.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock. It is common for executives to receive stock options or restricted stock units as part of their compensation packages, and their subsequent exercise or sale of these securities is a normal part of corporate governance.

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company.

Key Dates